ClinConnect ClinConnect Logo
Search / Trial NCT06047457

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

Launched by IPSEN · Sep 14, 2023

Trial Information

Current as of July 23, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of a medication called Dysport® to help prevent episodic migraines in adults. Episodic migraines are defined as having less than 15 migraine days a month, with at least 6 of those days being migraines. Dysport® works by blocking certain chemicals in the brain that cause pain during a migraine. Participants in the study will receive injections either of Dysport® or a placebo (which looks the same but has no active ingredients) over a total of 60 weeks, with several visits to the clinic and some online check-ins.

To be eligible for the trial, participants must be at least 18 years old, have a history of migraines for more than a year, and currently experience fewer than 15 headache days a month with at least 6 of those being migraine days. Throughout the study, participants will keep a diary of their headaches and may undergo some medical tests. It's important to note that certain medications and conditions may exclude someone from participating, so anyone interested should review the eligibility requirements carefully.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria :
  • must be ≥18 years of age inclusive, at the time of signing the informed consent and privacy/data protection documentation.
  • Participant has a diagnosis for more than 12 months, prior to screening visit, of migraine with aura or migraine without aura according to the International Classification of Headache Disorders definition and diagnostic criteria
  • Migraine onset occurred when participant was \<50 years of age.
  • Has baseline number of monthly headache days (MHD) of \<15 and baseline number of monthly migraine days (MMD) of ≥6, using eDiary data collected during the 4 weeks nearest to randomisation on Day 1 (but prior to randomisation).
  • Has baseline number of valid diary days ≥22 days collected during the 4 weeks nearest to randomisation on Day 1.
  • Participant must have previously used, or is currently using, preventive treatment for migraine (pharmacological) (i.e. non-naïve) prior to start of screening eDiary
  • Exclusion Criteria :
  • History or current diagnosis of migraine with brainstem aura, retinal migraine, complications of migraine, tension-type headache, trigeminal autonomic cephalalgias, hypnic headache, hemicrania continua, or new daily persistent headache.
  • Headache attributed to another disorder (e.g. secondary headaches), except medication overuse headache, which is permitted.
  • * Use of any of the following medications in the specified timeframe prior to start of the screening daily headache eDiary:
  • a. Within 24 weeks
  • i. Botulinum toxin for migraine (or for any other medical/aesthetic reason within 16 weeks)
  • b. Within 12 weeks
  • i. CGRP antagonists (monoclonal antibody or gepant) for preventive treatment of migraine (acute treatment of headache/migraine with a gepant is permitted, but limited to no more than 6 days per month (i.e. 6 days per each 4-week period with gepant intake))
  • ii. Cannabinol or other types of cannabinoids
  • c. Within 4 weeks
  • i. Anaesthetic or steroid injection in any region targeted for injection with study intervention
  • ii. Use of medical device to treat migraine (e.g. non-invasive neuromodulation therapies such as nerve stimulation (gammaCore), transcranial magnetic stimulation (cephaly), external trigeminal nerve stimulation, transcutaneous electrical nerve stimulation, and peripheral neuroelectrical stimulation)
  • iii. Other interventions for migraine assessed to interfere with study evaluations (e.g. acupuncture in head and neck region, cranial traction, nociceptive trigeminal inhibition, occipital nerve block treatments, and dental splints for headache) iv. Use of opioids or barbiturates for more than 2 days/month.
  • Note: participants are permitted to take one concomitant migraine preventative treatment (not listed above); however, the dose of this medication should be stable for ≥3 months before start of the screening eDiary.
  • • Known history of treatment failure to more than four medications prescribed for the prevention of migraine (two of which have different mechanisms of action) or known history of treatment failure to botulinum toxin prescribed for the prevention of migraine.

About Ipsen

Ipsen is a global biopharmaceutical group dedicated to innovation and specialty care, focusing on the discovery, development, and commercialization of transformative medicines for patients with serious diseases. With a strong emphasis on oncology, neuroscience, and rare diseases, Ipsen leverages cutting-edge research and advanced technologies to deliver high-quality therapies that address unmet medical needs. Committed to scientific excellence and ethical practices, Ipsen collaborates with healthcare professionals and stakeholders to drive patient-centered solutions and improve health outcomes worldwide.

Locations

Madrid, , Spain

Rochester, New York, United States

Media, Pennsylvania, United States

Berlin, , Germany

Houston, Texas, United States

Chicago, Illinois, United States

Asheville, North Carolina, United States

Rochester, New York, United States

Fullerton, California, United States

Cordova, Tennessee, United States

Hialeah, Florida, United States

Orange, California, United States

Brooklyn, New York, United States

New Albany, Ohio, United States

Farmington Hills, Michigan, United States

Krakow, , Poland

Greifswald, , Germany

Zaragoza, , Spain

Scottsdale, Arizona, United States

Barcelona, , Spain

Valencia, , Spain

Boston, Massachusetts, United States

Riverwoods, Illinois, United States

Canoga Park, California, United States

Katowice, , Poland

Ostrava, , Czechia

Colton, California, United States

Chesterfield, Missouri, United States

Hollywood, Florida, United States

Salt Lake City, Utah, United States

Birmingham, Alabama, United States

Tampa, Florida, United States

Winter Park, Florida, United States

Frisco, Texas, United States

Tbilisi, , Georgia

Tbilisi, , Georgia

Burnsville, Minnesota, United States

Frisco, Texas, United States

Foxboro, Massachusetts, United States

Cincinnati, Ohio, United States

Plano, Texas, United States

Miami Beach, Florida, United States

Madrid, , Spain

Jihlava, , Czechia

Franklin, Tennessee, United States

Málaga, , Spain

Krakow, , Poland

Dallas, Texas, United States

Chicago, Illinois, United States

Phoenix, Arizona, United States

New Haven, Connecticut, United States

Red Deer, , Canada

Berlin, , Germany

Decatur, Georgia, United States

West Valley City, Utah, United States

Hallandale Beach, Florida, United States

Kingwood, West Virginia, United States

Tbilisi, , Georgia

Aventura, Florida, United States

Fort Wayne, Indiana, United States

Hendersonville, North Carolina, United States

Tbilisi, , Georgia

Montréal, , Canada

Tempe, Arizona, United States

North Charleston, South Carolina, United States

Fullerton, California, United States

Hollywood, Florida, United States

Sarnia, , Canada

Batumi, , Georgia

Tbilisi, , Georgia

East Hartford, Connecticut, United States

Savannah, Georgia, United States

Brookline, Massachusetts, United States

Poughkeepsie, New York, United States

Philadelphia, Pennsylvania, United States

Fairfax, Virginia, United States

Columbia, Washington, United States

Montréal, , Canada

Savannah, California, United States

Birmingham, Alabama, United States

Phoenix, Arizona, United States

Scottsdale, Arizona, United States

Tempe, Arizona, United States

Fullerton, California, United States

Fullerton, California, United States

Orange, California, United States

Aventura, Florida, United States

Hialeah, Florida, United States

Hollywood, Florida, United States

Miami, Florida, United States

Tampa, Florida, United States

Winter Park, Florida, United States

Savannah, Georgia, United States

Riverwoods, Illinois, United States

Fort Wayne, Indiana, United States

Burnsville, Minnesota, United States

Chesterfield, Missouri, United States

Brooklyn, New York, United States

Poughkeepsie, New York, United States

Rochester, New York, United States

Hendersonville, North Carolina, United States

New Albany, Ohio, United States

Philadelphia, Pennsylvania, United States

Cordova, Tennessee, United States

Frisco, Texas, United States

Houston, Texas, United States

Plano, Texas, United States

Salt Lake City, Utah, United States

West Valley City, Utah, United States

Columbia, Washington, United States

Montréal, , Canada

Red Deer, , Canada

Sarnia, , Canada

Brno, , Czechia

Brno, , Czechia

Jihlava, , Czechia

Praha 8, , Czechia

Praha, , Czechia

Batumi, , Georgia

Tbilisi, , Georgia

Tbilisi, , Georgia

Tbilisi, , Georgia

Tbilisi, , Georgia

Tbilisi, , Georgia

Berlin, , Germany

Berlin, , Germany

Greifswald, , Germany

München, , Germany

Bydgoszcz, , Poland

Gdynia, , Poland

Katowice, , Poland

Lublin, , Poland

Madrid, , Spain

Málaga, , Spain

Valencia, , Spain

Zaragoza, , Spain

Savannah, California, United States

Boston, Massachusetts, United States

Asheville, North Carolina, United States

Chocen, , Czechia

Amiens, , France

Nîmes, , France

Paris, , France

Krakow, , Poland

Krakow, , Poland

Krakow, , Poland

Oświęcim, , Poland

Madrid, , Spain

Winter Park, Florida, United States

Praha, , Czechia

Farmington Hills, Michigan, United States

North Charleston, South Carolina, United States

Fairfax, Virginia, United States

Praha, , Czechia

Praha, , Czechia

Greensboro, Georgia, United States

Worcester, Massachusetts, United States

Media, Pennsylvania, United States

Dallas, Texas, United States

Decatur, Georgia, United States

Frederick, Maryland, United States

Kingwood, West Virginia, United States

Greensboro, Georgia, United States

Frederick, Maryland, United States

Worcester, Massachusetts, United States

New Albany, Ohio, United States

Dallas, Texas, United States

Salt Lake City, Utah, United States

Red Deer, , Canada

Sarnia, , Canada

Brno, , Czechia

Brno, , Czechia

Praha 8, , Czechia

Praha, , Czechia

München, , Germany

Bydgoszcz, , Poland

Gdynia, , Poland

Lublin, , Poland

Savannah, California, United States

Winter Park, Florida, United States

Frisco, Texas, United States

Chocen, , Czechia

Praha, , Czechia

Amiens, , France

Nîmes, , France

Paris, , France

Krakow, , Poland

Oświęcim, , Poland

Hessen, , Germany

Westborough, Massachusetts, United States

Jacksonville, Florida, United States

Orlando, Florida, United States

Wooster, Ohio, United States

Jackson, Tennessee, United States

San Diego, California, United States

Winter Haven, Florida, United States

Las Vegas, Nevada, United States

Las Vegas, Nevada, United States

Greenfield, Wisconsin, United States

Neenah, Wisconsin, United States

Patients applied

0 patients applied

Trial Officials

Ipsen Medical Director

Study Director

Ipsen

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported